Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience

A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil

“…Three national studies have shown SVR rates between 90% and 98% after treatment of liver-transplanted patients with CHC using DAAs [19][20][21] .The characteristics of the transplanted patients with CHC included in this study, i.e., associated predominantly with HCV genotype 1 and mild fibrosis, can justify the high SVR rates, very similar to those found by Araujo et al 20 and Zanaga et al 21 . In fact, in a study carried out in Sao Paulo including 53 patients, 23% of which had mild fibrosis (F0-F1), while 43% presented with moderate fibrosis (F2), the SVR rate was 98%, with virological failure occurring only in one cirrhotic patient 21 .…”

“…Based on previously published literature, there are reports on the treatment of HCV infections with DAAs in Brazil, reaching SVR rates between 92% and 95% [15][16][17][18] . However, only three studies included exclusively liver transplantrecipients, all in the South and Southeast regions of the country [19][20][21] . This study aimed to describe the SVR rates after treatment of patients with CHC having undergone liver transplantation and treatment with sofosbuvir and daclatasvir or simeprevir, with or without RBV, in a real life study in the Brazilian Northeast region.…”

Applicability of the medication level variability index (MLVI) in adult hepatic transplantation and association with graft rejection rates

“…The hypothesis of lymphocytic exhaustion induced by virus C was considered, which would be restored after treatment, and therefore, those patients would be more susceptible to the occurrence of rejection. 24 However, in a study by Saxena et al, 2017 also assessing the treatment of hepatitis C in transplant recipients, the rate of acute rejection was similar to that found in patients after transplantation who were not treating HCV. 25 When comparing adherence to treatment with immunosuppressant between young adults and elderly liver transplanted recipients, Leven et al, 2017 found better adherence in the elderly (≥ 65 years), in addition to noting that they did not have an increased risk for rejection.…”